Non-Hodgkin lymphoma comprises a heterogeneous group of haematological malignancies, classified according to their clinic, anatomic-pathological features and, lately, to their molecular biomarkers. Despite the therapeutic advances, nearly half of the patients will die because of this disease. The new diagnostic tools have been the cornerstone to design recent therapy targets, which must be included in the current treatment guidelines of this sort of neoplasms by means of clinical trials and evidence-based medicine.
View Article and Find Full Text PDFWe describe our experience of the Instituto Nacional de Cancerología in Mexico City in the management of 22 healthy donors of the allogeneic bone marrow transplantation program. Twenty three bone marrow products were harvested from the 22 healthy donors (7 male, 15 female) with a median age of 26 (range 16 to 47). All were seronegative for HIV, HBV and HCV.
View Article and Find Full Text PDF